Parasites in Immunocompromised Hosts

Several parasites are efficiently controlled, or entirely asymptomatic, in an immunocompetent host. They become capable of severe, disseminated, or life-threatening disease once specific components of host immunity are lost.

The pattern of vulnerability is not uniform. Different parasites depend on different arms of the immune system for control, so different types of immunosuppression unmask different organisms.

Cell-mediated (Th1-type) immunity, driven by interferon-gamma and effective macrophage activation, is the principal defence against intracellular protozoa capable of chronic latency. Its loss is the dominant mechanism behind reactivation of Toxoplasma and behind the more severe presentations of Cryptosporidium and microsporidial infection.

The classic cause of this loss is advanced HIV infection with low CD4 counts. Organ transplantation immunosuppression and other causes of T-cell dysfunction also contribute.

A distinct mechanism, Th2-dependent regulation of larval autoinfection, underlies the specific vulnerability to Strongyloides hyperinfection. It is triggered less by classical cellular immunodeficiency in the HIV sense and more specifically by corticosteroid therapy and HTLV-1 co-infection.

"Immunosuppression" is therefore not a single uniform state. It is a collection of distinct functional deficits, each of which opens a different, organism-specific vulnerability.

Toxoplasma gondii establishes lifelong tissue cysts containing dormant bradyzoites in a very large proportion of exposed individuals. Seroprevalence exceeds a third to half of adults in many populations. The great majority carry this latent infection without any awareness of it.

In the setting of significant cell-mediated immune impairment, bradyzoites convert back to actively replicating, tissue-destructive tachyzoites. This produces reactivation disease, which is far more common in this population than severe primary infection. It is the dominant clinical pattern of toxoplasmosis in immunocompromised hosts overall.

The central nervous system is the most frequent site of reactivation. It produces toxoplasmic encephalitis with focal neurological deficits and, characteristically, multiple ring-enhancing lesions on imaging. It occurs predominantly at CD4 counts below roughly 100 cells per microlitre in HIV-associated disease and is a recognised AIDS-defining illness.

This reactivation risk is why seropositive patients with advanced HIV-related immunosuppression are considered for prophylactic therapy. It is also why unexplained focal CNS lesions in this population routinely prompt consideration of toxoplasmic encephalitis alongside primary CNS lymphoma.

Strongyloides stercoralis can persist indefinitely within a single host through its unique autoinfective cycle. Larvae transform to the infective stage and reinvade the same host internally, without requiring any new external exposure. Chronic, low-grade infection can continue silently for decades.

Loss of the host immune control that normally restrains this autoinfective cycle allows dramatic acceleration of larval transformation and reinvasion. This produces hyperinfection syndrome, an intensified but still anatomically confined process. It affects the gastrointestinal tract, lungs, and skin, corresponding to the organs of the normal migratory cycle.

Further escalation produces disseminated strongyloidiasis. Larvae migrate beyond the normal life cycle route to invade essentially any organ.

Migrating larvae characteristically carry enteric Gram-negative bacteria across the breached intestinal mucosal barrier. This produces secondary Gram-negative bacteraemia, sepsis, and, if larvae reach the meninges, bacterial meningitis. These complications can dominate and obscure the underlying parasitic diagnosis if Strongyloides is not specifically considered.

Corticosteroid therapy, even at modest doses and relatively short courses, is the single most important and best-established trigger. It acts through suppression of the Th2-driven immune mechanisms that normally limit the autoinfective cycle.

HTLV-1 co-infection is a further, specifically potent risk factor. It appears to impair Strongyloides-relevant immunity more profoundly than many other causes of immunosuppression. HIV is a comparatively weaker risk factor for hyperinfection than might otherwise be expected.

Because of this risk, screening or empirical treatment for Strongyloides is specifically recommended before starting significant corticosteroid therapy in anyone with plausible exposure to an endemic area, however remote in time.

Cryptosporidium species, most importantly Cryptosporidium parvum and Cryptosporidium hominis, are apicomplexan protozoa. They are transmitted by the faecal-oral route via ingestion of oocysts, most often through contaminated drinking or recreational water.

The oocysts are markedly resistant to standard chlorination. Cryptosporidium is therefore a recognised cause of waterborne outbreaks, even in municipal water systems meeting conventional treatment standards.

Following ingestion, sporozoites are released and invade the intestinal epithelium. The parasite undergoes both asexual and sexual replication cycles in a distinctive intracellular but extracytoplasmic location. This is within a parasitophorous vacuole just beneath the host cell surface membrane, rather than deeper within the cytoplasm.

The cycle produces new oocysts that are shed in stool. Thin-walled oocysts release sporozoites directly within the intestine and can also cause ongoing autoinfection within the same host.

In immunocompetent hosts, Cryptosporidium infection typically produces a self-limited watery diarrhoeal illness lasting one to two weeks, often with abdominal cramping and low-grade fever. It resolves without specific antiparasitic treatment as host immunity, predominantly cell-mediated, brings the infection under control.

In individuals with significant cell-mediated immune impairment, particularly advanced HIV infection with low CD4 counts, Cryptosporidium instead produces chronic, severe, high-volume watery diarrhoea that can persist for months. This leads to marked dehydration, electrolyte disturbance, and profound weight loss and wasting.

It was historically a major cause of morbidity and mortality in advanced, untreated HIV infection, before the widespread availability of effective antiretroviral therapy. Antiretroviral therapy remains the most effective way to control the infection in this population, by restoring the underlying cell-mediated immune deficit.

Cystoisospora belli (formerly classified as Isospora belli) is a further apicomplexan intestinal protozoan. It is also transmitted by ingestion of oocysts via the faecal-oral route.

It parallels Cryptosporidium closely, biologically and clinically, in its behaviour in immunocompromised hosts. It is generally less common overall and shows some geographic and epidemiological differences in distribution.

Following ingestion, the organism invades small intestinal epithelial cells and undergoes both asexual and sexual reproductive cycles. Oocysts are shed unsporulated in stool and require a period of environmental maturation before becoming infective. This distinguishes its shed-stage biology somewhat from the immediately infective oocysts of Cryptosporidium.

In immunocompetent individuals, infection is typically self-limited, producing watery diarrhoea and abdominal pain. The course is occasionally more prolonged and relapsing than typical Cryptosporidium infection, but resolves with intact host immunity.

In immunocompromised hosts, particularly advanced HIV infection, Cystoisospora produces chronic, severe, and sometimes markedly prolonged diarrhoeal illness with significant fluid loss and wasting. The clinical severity closely parallels that seen with Cryptosporidium in the same population.

Distinctively among these organisms, Cystoisospora is specifically associated with prominent peripheral blood eosinophilia in a proportion of cases. This is a somewhat unusual feature for a protozoan infection and a point of diagnostic interest distinguishing it from the other organisms.

Microsporidia are a distinct group of obligate intracellular, spore-forming organisms with a unique and highly specialised invasion mechanism. Each spore contains a coiled polar tubule that everts explosively on contact with a suitable host cell. It injects infective sporoplasm directly into the host cell cytoplasm, a mode of cellular invasion unlike that of any of the other organisms.

Enterocytozoon bieneusi and Encephalitozoon intestinalis are the species most relevant to human intestinal disease. They are transmitted via ingestion of environmentally resistant spores, most often through contaminated water or food. Replication then occurs within intestinal epithelial cells.

In immunocompetent hosts, microsporidial infection is generally mild, self-limited, or entirely asymptomatic. Given its typically minor clinical impact in this population, it is often not specifically sought or diagnosed.

In individuals with advanced cell-mediated immune impairment, again most classically advanced HIV infection, microsporidiosis produces chronic diarrhoea and malabsorption. The pattern is clinically similar to Cryptosporidium and Cystoisospora infection in the same population.

Encephalitozoon intestinalis in particular has a recognised capacity to disseminate beyond the gastrointestinal tract in severely immunocompromised hosts. It produces disease in the urinary tract, respiratory tract, and other sites. This distinguishes it from the more gut-confined pattern typical of Enterocytozoon bieneusi infection.

Diagnosis requires specific staining techniques (modified trichrome or chromotrope-based stains), given the very small spore size that is easily missed on routine stool examination. Electron microscopy and molecular methods give definitive species identification. This reflects the organism's diminutive size and distinctive structure relative to the other protozoa.